Patent · US Active

Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

US11234994B2 · kind B2 · utility

0Cited by

19References

21Claims

0Family size

Assignee

Benitec Biopharma Limited · AU

Inventors

David Suhy · San Ramon, US
Michael Wayne Graham · Jindalee, AU
CAPUCINE TROLLET · Paris, FR
Alberto Malerba · Egham, GB
John George Dickson · Leatherhead, GB

Key dates

Filing date	Apr 13, 2017
Grant date	Feb 1, 2022
Priority date	—
Expiry date	Sep 24, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.